?? VeinTech Partners with NEMIC to Transform Vascular Access in the US! ??????????
We are thrilled to announce that VeinTech has partnered with the The New England Medical Innovation Center (NEMIC) in Providence, Rhode Island, marking our official entry into the US market! This collaboration makes VeinTech the first Perth based company to utilize the biobridge established between Western Australia and Rhode Island as part of an MoU signed between Perth Biodesign and NEMIC in March 2024, unlocking significant opportunities for healthcare innovation across continents. Thank you to everyone who have facilitated this partnership - Peter Traianou Michael Pereira Stephen Dawson Kevin Pfleger Aidan Petrie Lydia Shin Schroter, MBA Maey Petrie Andrew Williamson.
Here’s what our leaders have to say about this exciting milestone:
?? Dr. Nikhilesh Bappoo, Co-Founder & Co-CEO:
“Our goal is to impact the most common invasive medical procedure on the planet. This partnership with NEMIC will enable us to effectively deliver our novel medical technologies to underserved patients in the US market. NEMIC was a no-brainer to call home after our recent visit to Providence.”
?? Peter Traianou, Chairman:
“Right vein, first time, every time. Simple words but powerful for anyone who has experienced failed cannula insertions. This partnership with NEMIC and Rhode Island allows us to accelerate development, solve a global problem, and bring VeinTech’s solution to the US market. The potential is enormous!”
?? A/Prof Peter Carr, Clinical Advisor and Vascular Access Expert:
"This partnership will not only disrupt current practices but act as a catalyst for further innovation in vascular access and infusion therapy. VeinTech's novel approach to ultrasound-guided PIVC insertion is just the beginning. This partnership will be further enhanced by VeinTech’s existing European connections through Ireland facilitating cross-Atlantic collaboration and catalyse a surge in related technologies and complementary solutions, whilst enabling rapid commercialization and global adoption."
?? Why this matters:
Peripheral intravenous catheter (PIVC) insertion is the most common invasive procedure in hospitals, performed 1 billion times annually. Yet, first-attempt failure rates can reach 40%, causing discomfort, inefficiencies, and increased healthcare costs.
?? Learn more about our mission: www.veintech.com.au
Nicholas Buckley Katherine Arenson Jamie Davison
WA Life Sciences Innovation Hub MTPConnect Tracey Wilkinson Roop Judge Stuart Dignam
RI Life Science Hub Patrice Milos, PhD Lilia Kirtley Holt
Government of Western Australia Department of Jobs, Tourism, Science and Innovation Natasha M. Kim Wiltshire
Australian Trade and Investment Commission (Austrade) Steven Spezza Stefanie Small Clark, MID
AmCham Australia Natalie Meyer